Business Context and Reporting Period
Company: Oragenics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 30, 2013
Event: Entry into a Material Definitive Agreement with Intrexon Corporation.
On September 30, 2013, Oragenics entered into a worldwide Exclusive Channel Collaboration Agreement (ECC) with Intrexon Corporation. The agreement focuses on developing and commercializing genetically modified probiotics for treating diseases of the oral cavity, throat, sinus, and esophagus, including aphthous stomatitis and Behcet's disease. Oragenics will utilize Intrexon's proprietary technology for cell identification, design, and production.
Key Financial Metrics and Transaction Details
This filing details a specific transaction rather than periodic financial performance. Key financial terms include:
- Private Placement Proceeds: Oragenics sold 1.3 million shares of common stock to Intrexon at $3.00 per share, generating gross proceeds of $3.9 million.
- Technology Access Shares: Oragenics issued 1,348,510 shares of common stock to Intrexon as consideration for the ECC.
- Convertible Promissory Note: Oragenics issued a note to Intrexon in the principal amount of $1,956,000, maturing on December 31, 2013. The note is convertible into common stock at the closing price on the last trading day prior to conversion, subject to shareholder approval.
- Revenue Sharing: Oragenics agreed to pay Intrexon 10% of net sales derived from products developed under the collaboration.
- Use of Proceeds: Funds from the stock sale are designated for the probiotic program development and general corporate purposes.
Note: The filing does not provide standard financial metrics such as total revenue, net profit, operating cash flow, or total debt for the company as of the reporting date.
Material Changes and Milestone Obligations
The agreement establishes significant future contingent liabilities based on development milestones. Oragenics must pay Intrexon the following upon achievement of specific events:
- Phase II Milestone: $2,000,000 payable within 30 days of the first dosing of a patient in a Phase II clinical trial.
- Phase III Milestone: $5,000,000 payable within 30 days of meeting the primary endpoint in a Phase III clinical trial.
- Approval/Commercialization Milestone: $10,000,000 payable within 30 days of the first commercial sale or regulatory approval (FDA or equivalent).
Payments may be made in cash or shares of Oragenics common stock based on fair market value, at Oragenics' option. If Oragenics is sold prior to paying these milestones, all subsequent payments must be made in cash.
Outlook, Risks, and Contingencies
Management Commentary and Strategy: The collaboration is intended to accelerate the development of probiotics for specific diseases using Intrexon's technology. Oragenics retains responsibility for funding development, clinical trials, and commercialization, while Intrexon handles technology discovery and cell-engineering.
Risks and Contingencies:
- Termination Rights: Oragenics may terminate the agreement with 90 days' written notice. Intrexon may terminate if Oragenics breaches the agreement (uncured within 60 days) or fails to pursue a "Superior Therapy" identified by Intrexon.
- Standstill Provision: Intrexon has agreed to a three-year standstill, restricting it from seeking control, initiating mergers, or soliciting proxies without Oragenics' invitation.
- Regulatory Approval: Future payments and commercialization depend on successful clinical trials and regulatory approvals, which are not guaranteed.
- Confidential Treatment: Portions of the ECC agreement have been redacted and filed separately under confidential treatment.
Investor Verification Checklist
- Verify the current status of the $1,956,000 Convertible Promissory Note and whether shareholder approval for conversion has been obtained.
- Confirm the dilution impact of the 1,348,510 Technology Access Shares and the 1.3 million shares sold in the private placement.
- Monitor progress toward the Phase II clinical trial milestone to assess the timing of the $2 million contingent payment.
- Review the full text of the Exclusive Channel Collaboration Agreement (Exhibit 10.1) for specific definitions of "Superior Therapy" and termination conditions.
- Assess the company's cash runway given the obligation to fund all development and commercialization costs under the agreement.